Kura Oncology, Inc. (KURA) to Post FY2019 Earnings of $4.83 Per Share, Oppenheimer Holdings Forecasts

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Oppenheimer Holdings issued their FY2019 EPS estimates for shares of Kura Oncology in a research report issued on Tuesday. Oppenheimer Holdings analyst L. Cann expects that the firm will post earnings of $4.83 per share for the year. Oppenheimer Holdings currently has a “Outperform” rating and a $18.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Kura Oncology’s FY2020 earnings at $11.12 EPS and FY2021 earnings at $12.04 EPS.

KURA has been the topic of several other reports. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “sell” rating in a report on Saturday. Leerink Swann reaffirmed an “outperform” rating on shares of Kura Oncology in a report on Monday, November 7th. Finally, Cann boosted their target price on shares of Kura Oncology to $18.00 and gave the company an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Kura Oncology has a consensus rating of “Buy” and an average price target of $13.95.

ILLEGAL ACTIVITY NOTICE: This piece was reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another site, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be read at http://sleekmoney.com/kura-oncology-inc-kura-to-post-fy2019-earnings-of-4-83-per-share-oppenheimer-holdings-forecasts/1655983.html.

Shares of Kura Oncology (NASDAQ:KURA) remained flat at $6.65 during trading on Thursday. The company’s stock had a trading volume of 15,842 shares. The firm’s market cap is $126.65 million. The stock’s 50-day moving average price is $6.23 and its 200-day moving average price is $5.59. Kura Oncology has a one year low of $2.50 and a one year high of $7.24.

ILLEGAL ACTIVITY NOTICE: This piece was reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another site, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be read at http://sleekmoney.com/kura-oncology-inc-kura-to-post-fy2019-earnings-of-4-83-per-share-oppenheimer-holdings-forecasts/1655983.html.

A hedge fund recently bought a new stake in Kura Oncology stock. Pillar Pacific Capital Management LLC acquired a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 30,500 shares of the company’s stock, valued at approximately $191,000. Pillar Pacific Capital Management LLC owned about 0.16% of Kura Oncology as of its most recent filing with the SEC. Institutional investors own 45.68% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

5 Day Chart for NASDAQ:KURA

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/kura-oncology-inc-kura-to-post-fy2019-earnings-of-4-83-per-share-oppenheimer-holdings-forecasts/1655983.html

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *